313 related articles for article (PubMed ID: 29418079)
1. Concise Review: Chronic Myeloid Leukemia: Stem Cell Niche and Response to Pharmacologic Treatment.
Arrigoni E; Del Re M; Galimberti S; Restante G; Rofi E; Crucitta S; Baratè C; Petrini M; Danesi R; Di Paolo A
Stem Cells Transl Med; 2018 Mar; 7(3):305-314. PubMed ID: 29418079
[TBL] [Abstract][Full Text] [Related]
2. Overcoming BCR::ABL1 dependent and independent survival mechanisms in chronic myeloid leukaemia using a multi-kinase targeting approach.
Busch C; Mulholland T; Zagnoni M; Dalby M; Berry C; Wheadon H
Cell Commun Signal; 2023 Nov; 21(1):342. PubMed ID: 38031192
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow niche trafficking of miR-126 controls the self-renewal of leukemia stem cells in chronic myelogenous leukemia.
Zhang B; Nguyen LXT; Li L; Zhao D; Kumar B; Wu H; Lin A; Pellicano F; Hopcroft L; Su YL; Copland M; Holyoake TL; Kuo CJ; Bhatia R; Snyder DS; Ali H; Stein AS; Brewer C; Wang H; McDonald T; Swiderski P; Troadec E; Chen CC; Dorrance A; Pullarkat V; Yuan YC; Perrotti D; Carlesso N; Forman SJ; Kortylewski M; Kuo YH; Marcucci G
Nat Med; 2018 May; 24(4):450-462. PubMed ID: 29505034
[TBL] [Abstract][Full Text] [Related]
4. System analysis of Huang-Lian-Jie-Du-Tang and their key active ingredients for overcoming CML resistance by suppression of leukemia stem cells.
Huang G; Yin Z; Wang X; Wen Z; Su R; Li C; Liu Y; Yang J; Hu H; Nie H; Zeng X; Fei J
Phytomedicine; 2023 Aug; 117():154918. PubMed ID: 37329755
[TBL] [Abstract][Full Text] [Related]
5. Mesenchymal Niche-Specific Expression of Cxcl12 Controls Quiescence of Treatment-Resistant Leukemia Stem Cells.
Agarwal P; Isringhausen S; Li H; Paterson AJ; He J; Gomariz Á; Nagasawa T; Nombela-Arrieta C; Bhatia R
Cell Stem Cell; 2019 May; 24(5):769-784.e6. PubMed ID: 30905620
[TBL] [Abstract][Full Text] [Related]
6. Targeting BMP signaling in the bone marrow microenvironment of myeloid leukemia.
Lefort S; Maguer-Satta V
Biochem Soc Trans; 2020 Apr; 48(2):411-418. PubMed ID: 32167132
[TBL] [Abstract][Full Text] [Related]
7. Contribution of BCR-ABL molecular variants and leukemic stem cells in response and resistance to tyrosine kinase inhibitors: a review.
Al Hamad M
F1000Res; 2021; 10():1288. PubMed ID: 35284066
[TBL] [Abstract][Full Text] [Related]
8. Microenvironmental protection of CML stem and progenitor cells from tyrosine kinase inhibitors through N-cadherin and Wnt-β-catenin signaling.
Zhang B; Li M; McDonald T; Holyoake TL; Moon RT; Campana D; Shultz L; Bhatia R
Blood; 2013 Mar; 121(10):1824-38. PubMed ID: 23299311
[TBL] [Abstract][Full Text] [Related]
9. Deregulated expression of miR-29a-3p, miR-494-3p and miR-660-5p affects sensitivity to tyrosine kinase inhibitors in CML leukemic stem cells.
Salati S; Salvestrini V; Carretta C; Genovese E; Rontauroli S; Zini R; Rossi C; Ruberti S; Bianchi E; Barbieri G; Curti A; Castagnetti F; Gugliotta G; Rosti G; Bergamaschi M; Tafuri A; Tagliafico E; Lemoli R; Manfredini R
Oncotarget; 2017 Jul; 8(30):49451-49469. PubMed ID: 28533480
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia stem cells: targeting therapeutic implications.
Mojtahedi H; Yazdanpanah N; Rezaei N
Stem Cell Res Ther; 2021 Dec; 12(1):603. PubMed ID: 34922630
[TBL] [Abstract][Full Text] [Related]
11. Novel HDAC inhibitor MAKV-8 and imatinib synergistically kill chronic myeloid leukemia cells via inhibition of BCR-ABL/MYC-signaling: effect on imatinib resistance and stem cells.
Lernoux M; Schnekenburger M; Losson H; Vermeulen K; Hahn H; Gérard D; Lee JY; Mazumder A; Ahamed M; Christov C; Kim DW; Dicato M; Bormans G; Han BW; Diederich M
Clin Epigenetics; 2020 May; 12(1):69. PubMed ID: 32430012
[TBL] [Abstract][Full Text] [Related]
12. Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia.
Muselli F; Peyron JF; Mary D
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31717629
[TBL] [Abstract][Full Text] [Related]
13. PP2A-activating drugs selectively eradicate TKI-resistant chronic myeloid leukemic stem cells.
Neviani P; Harb JG; Oaks JJ; Santhanam R; Walker CJ; Ellis JJ; Ferenchak G; Dorrance AM; Paisie CA; Eiring AM; Ma Y; Mao HC; Zhang B; Wunderlich M; May PC; Sun C; Saddoughi SA; Bielawski J; Blum W; Klisovic RB; Solt JA; Byrd JC; Volinia S; Cortes J; Huettner CS; Koschmieder S; Holyoake TL; Devine S; Caligiuri MA; Croce CM; Garzon R; Ogretmen B; Arlinghaus RB; Chen CS; Bittman R; Hokland P; Roy DC; Milojkovic D; Apperley J; Goldman JM; Reid A; Mulloy JC; Bhatia R; Marcucci G; Perrotti D
J Clin Invest; 2013 Oct; 123(10):4144-57. PubMed ID: 23999433
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic Reprogramming Sensitizes CML Stem Cells to Combined EZH2 and Tyrosine Kinase Inhibition.
Scott MT; Korfi K; Saffrey P; Hopcroft LE; Kinstrie R; Pellicano F; Guenther C; Gallipoli P; Cruz M; Dunn K; Jorgensen HG; Cassels JE; Hamilton A; Crossan A; Sinclair A; Holyoake TL; Vetrie D
Cancer Discov; 2016 Nov; 6(11):1248-1257. PubMed ID: 27630125
[TBL] [Abstract][Full Text] [Related]
15. Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia: Is It Worth the Effort?
Soverini S; De Santis S; Monaldi C; Bruno S; Mancini M
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34209376
[TBL] [Abstract][Full Text] [Related]
16. Integrin-Linked Kinase Mediates Therapeutic Resistance of Quiescent CML Stem Cells to Tyrosine Kinase Inhibitors.
Rothe K; Babaian A; Nakamichi N; Chen M; Chafe SC; Watanabe A; Forrest DL; Mager DL; Eaves CJ; Dedhar S; Jiang X
Cell Stem Cell; 2020 Jul; 27(1):110-124.e9. PubMed ID: 32413332
[TBL] [Abstract][Full Text] [Related]
17. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
18. Targeting DNMT1 by demethylating agent OR-2100 increases tyrosine kinase inhibitors-sensitivity and depletes leukemic stem cells in chronic myeloid leukemia.
Kamachi K; Ureshino H; Watanabe T; Yoshida N; Yamamoto Y; Kurahashi Y; Fukuda-Kurahashi Y; Hayashi Y; Hirai H; Yamashita S; Ushijima T; Okada S; Kimura S
Cancer Lett; 2022 Feb; 526():273-283. PubMed ID: 34875342
[TBL] [Abstract][Full Text] [Related]
19. Leukemic stem cells shall be searched in the bone marrow before "tyrosine kinase inhibitor-discontinuation" in chronic myeloid leukemia.
Ilhan O; Narli Ozdemir Z; Dalva K; Arslan A; Okay Ozgeyik M; Ipek S; Saydam G; Haznedaroglu IC
Int J Lab Hematol; 2021 Oct; 43(5):1110-1116. PubMed ID: 33834631
[TBL] [Abstract][Full Text] [Related]
20. Evi1 defines leukemia-initiating capacity and tyrosine kinase inhibitor resistance in chronic myeloid leukemia.
Sato T; Goyama S; Kataoka K; Nasu R; Tsuruta-Kishino T; Kagoya Y; Nukina A; Kumagai K; Kubota N; Nakagawa M; Arai S; Yoshimi A; Honda H; Kadowaki T; Kurokawa M
Oncogene; 2014 Oct; 33(42):5028-38. PubMed ID: 24747972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
